2752-7948

BMJ Oncology

BMJ

View prefix report (10.1136)

Health Score

0 Excellent

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 81 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Medium impact81 DOIs
2

Attach ORCID iDs across 7 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact7 DOIs
3

Deposit reference lists for 5 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact5 DOIs

DOIs for this ISSN

Showing the top 5 of 231 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Identifying the deficits in cancer care for people with inte… (10.1136/bmjonc-2023-000171)
Abstract
26.98 11
2 Shifting tides: the rising tide of early-onset cancers deman… (10.1136/bmjonc-2023-000106)
Abstract
26.03 10
3 Recall of ibrutinib and issues with therapeutic approval (10.1136/bmjonc-2024-000418)
Abstract
22.58 7
4 Addressing the hidden toxicities of cancer: a call to action… (10.1136/bmjonc-2024-000429)
Abstract
22.58 7
5 COVID-19 and cancer in the UK: which will prove to be the le… (10.1136/bmjonc-2022-000012)
Abstract
19.45 5
6 Globalisation of clinical trials in oncology: a double-edged… (10.1136/bmjonc-2023-000163)
Abstract
17.47 4
7 Updating the NHS cancer waiting time standards (10.1136/bmjonc-2024-000337)
Abstract
17.47 4
8 Research priorities to improve cancer care for people with i… (10.1136/bmjonc-2024-000395)
Abstract
17.47 4
9 Making administrative healthcare systems clinical data the f… (10.1136/bmjonc-2023-000038)
Abstract
15.05 3
10 Evidence-based practice in oncology, when it suits us? (10.1136/bmjonc-2023-000061)
Abstract
15.05 3
11 Guilty by association? The complex relationship between immu… (10.1136/bmjonc-2023-000127)
Abstract
15.05 3
12 Transforming the care of people with Lynch syndrome: a syste… (10.1136/bmjonc-2023-000211)
Abstract
15.05 3
13 Geriatric oncology in LMICs: it is time to mature (10.1136/bmjonc-2024-000537)
Abstract
15.05 3
14 Bridging the gap between guidelines and practice in Lynch sy… (10.1136/bmjonc-2025-000821)
Abstract
15.05 3
15 Symptoms, side effects, quality of life and financial toxici… (10.1136/bmjonc-2025-000879)
Abstract
15.05 3
16 WHO is embedding inequality into cancer diagnostics (10.1136/bmjonc-2025-000889)
Abstract
15.05 3
17 Endpoints for trials of adjuvant anticancer therapies (10.1136/bmjonc-2023-000179)
Abstract
11.93 2
18 Machine learning predicted fast progression after initiation… (10.1136/bmjonc-2023-000227)
Abstract
11.93 2
19 Need for a ‘VR-cebo’ and more robust evaluations of virtual… (10.1136/bmjonc-2023-000230)
Abstract
11.93 2
20 Careful take-off by the EQ-5D-5L tool in lung cancer: fly li… (10.1136/bmjonc-2024-000405)
Abstract
11.93 2
21 Availability of quality-of-life results for clinical decisio… (10.1136/bmjonc-2024-000406)
Abstract
11.93 2
22 Consideration of initial steps to implementation of prostate… (10.1136/bmjonc-2024-000579)
Abstract
11.93 2
23 Evaluating the genetic landscape of prostate cancer: new ins… (10.1136/bmjonc-2024-000717)
Abstract
11.93 2
24 Does radiation-induced lymphocytopenia matter? Developing a… (10.1136/bmjonc-2025-000745)
Abstract
11.93 2
25 Cancer in people with intellectual disability: lower inciden… (10.1136/bmjonc-2025-000845)
Abstract
11.93 2
26 Five years after CONSORT-AI, not much has changed: a call to… (10.1136/bmjonc-2025-000891)
Abstract
11.93 2
27 Digital twins in oncology: where we are and where we hope to… (10.1136/bmjonc-2025-000893)
Abstract
11.93 2
28 Inclusive oncological trials and targeted treatments cannot… (10.1136/bmjonc-2023-000051)
Abstract
7.53 1
29 Modern cancer trials still lack information about QoL impact… (10.1136/bmjonc-2023-000062)
Abstract
7.53 1
30 Another piece in the overdiagnosis jigsaw puzzle (10.1136/bmjonc-2023-000225)
Abstract
7.53 1
31 Time, location and function of hypoxia-inducible factors are… (10.1136/bmjonc-2023-000290)
Abstract
7.53 1
32 Does the evidence exist for the deployment of AI in cancer t… (10.1136/bmjonc-2024-000448)
Abstract
7.53 1
33 Determining fracture risk in patients exposed to immune chec… (10.1136/bmjonc-2024-000559)
Abstract
7.53 1
34 Souped-up natural killer (NK) cells for treating tough cance… (10.1136/bmjonc-2024-000685)
Abstract
7.53 1
35 Inferior control arms in oncology trials in LMICs: contextua… (10.1136/bmjonc-2025-000931)
Abstract
7.53 1
36 Rethinking cancer care in conflict settings: lessons from Uk… (10.1136/bmjonc-2025-001048)
Abstract
7.53 1
37 Welcome to <i>BMJ Oncology</i> (10.1136/bmjonc-2022-000011)
Abstract References ORCID
0.00 0
38 Bridging the gap: promoting equity and diversity in global o… (10.1136/bmjonc-2022-000013)
Abstract
0.00 0
39 Community-generated solutions to cancer inequity: recommenda… (10.1136/bmjonc-2022-000014)
0.00 2
40 Time trends in health-related quality of life assessment and… (10.1136/bmjonc-2022-000021)
0.00 19
41 Long-term opioid therapy trajectories and overdose in patien… (10.1136/bmjonc-2022-000023)
0.00 7
42 Use of immunosuppression and subsequent cancer incidence: co… (10.1136/bmjonc-2023-000037)
0.00 8
43 Screening for prostate cancer: evidence, ongoing trials, pol… (10.1136/bmjonc-2023-000039)
0.00 28
44 Global trends in incidence, death, burden and risk factors o… (10.1136/bmjonc-2023-000049)
0.00 242
45 Predictive biomarkers and specific immune responses of COVID… (10.1136/bmjonc-2023-000054)
0.00 0
46 PACT-UK (PAncreatic Cancer reporting Template–UK): a cross-s… (10.1136/bmjonc-2023-000055)
0.00 2
47 Prevalence of MRI lesions in men responding to a GP-led invi… (10.1136/bmjonc-2023-000057)
0.00 37
48 NISCAHN: a phase II trial of nivolumab in patients with sali… (10.1136/bmjonc-2023-000065)
0.00 5
49 Novel proteomics-based plasma test for early detection of mu… (10.1136/bmjonc-2023-000073)
0.00 27
50 Treatment-related acute toxicity with adjuvant systemic trea… (10.1136/bmjonc-2023-000081)
0.00 1